This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martin, D. R.
Right arrow Articles by Oster, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martin, D. R.
Right arrow Articles by Oster, P.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, April 2006, p. 486-491, Vol. 13, No. 4
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.4.486-491.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

The VR2 Epitope on the PorA P1.7-2,4 Protein Is the Major Target for the Immune Response Elicited by the Strain-Specific Group B Meningococcal Vaccine MeNZB

D. R. Martin,1* N. Ruijne,1 L. McCallum,1 J. O'Hallahan,2 and P. Oster3

Institute of Environmental Science and Research (ESR), Porirua, New Zealand,1 New Zealand Ministry of Health, Wellington, New Zealand,2 Chiron Vaccines, Siena, Italy3

Received 11 January 2006/ Returned for modification 6 February 2006/ Accepted 10 February 2006

A protracted epidemic of group B meningococcal disease in New Zealand led to the testing of a strain-specific tailor-made vaccine, MeNZB. Immunogenicity levels achieved during age group trials enabled New Zealand's regulatory authority to grant licensure to deliver MeNZB to all individuals under age 20. During the trials target strains for serum bactericidal antibody measurements included the vaccine target strain NZ98/254 and two comparator epidemic-type strains (NZ94/167 and NZ02/09). In this study, 12 other strains differing variously from the vaccine strain by their capsular group, PorB type, and PorA variable region specificities, or PorA expression, were used as target strains. The PorA specificity of the serum bactericidal antibody responses to the vaccine was determined for 40 vaccinees. Sets of 10 pre- and postvaccination sera were chosen randomly from the young infant, older infant, toddler, and school-age group trials. Antibody recognition of linearized PorA proteins was also determined using immunoblotting. Across all age groups vaccine-induced serum bactericidal antibodies specifically targeted the VR2 P1.4 epitope of the PorA P1.7-2,4 protein irrespective of the PorB type and/or capsular type of the target strain. Deletion of amino acids within the VR2 epitope or replacement of the epitope through genetic exchange allowed strains variously to resist antibody-directed complement-mediated lysis and negated PorA-specific antibody recognition in immunoblots. The demonstration that the immunodominant antibody response was specifically for the VR2 P1.4 epitope of the PorA protein supports the public health decision to use a strain-specific vaccine for the control of New Zealand's epidemic of meningococcal disease.

* Corresponding author. Mailing address: ESR, P.O. Box 50 348, Porirua, New Zealand. Phone: 64 4 914 0778. Fax: 64 4 914 0770. E-mail: diana.martin{at}esr.cri.nz.

Clinical and Vaccine Immunology, April 2006, p. 486-491, Vol. 13, No. 4
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.4.486-491.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Beernink, P. T., Granoff, D. M. (2008). Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines. Infect. Immun. 76: 2568-2575 [Abstract] [Full Text]  
  • Findlow, J., Holland, A., Andrews, N., Weynants, V., Sotolongo, F., Balmer, P., Poolman, J., Borrow, R. (2007). Comparison of Phenotypically Indistinguishable but Geographically Distinct Neisseria meningitidis Group B Isolates in a Serum Bactericidal Antibody Assay. CVI 14: 1451-1457 [Abstract] [Full Text]  
  • Wedege, E., Bolstad, K., Aase, A., Herstad, T. K., McCallum, L., Rosenqvist, E., Oster, P., Martin, D. (2007). Functional and Specific Antibody Responses in Adult Volunteers in New Zealand Who Were Given One of Two Different Meningococcal Serogroup B Outer Membrane Vesicle Vaccines. CVI 14: 830-838 [Abstract] [Full Text]  
  • Trotter, C., Findlow, J., Balmer, P., Holland, A., Barchha, R., Hamer, N., Andrews, N., Miller, E., Borrow, R. (2007). Seroprevalence of Bactericidal and Anti-Outer Membrane Vesicle Antibodies to Neisseria meningitidis Group B in England. CVI 14: 863-868 [Abstract] [Full Text]  
  • Ruijne, N., Lea, R. A., O'Hallahan, J., Oster, P., Martin, D. (2006). Understanding the Immune Responses to the Meningococcal Strain-Specific Vaccine MeNZB Measured in Studies of Infants.. CVI 13: 797-801 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»